Search our bibliography using the filters on the right-hand side.

Displaying 1 through 26 of 26 publications.
Sherrill B, Amonkar MM, Sherif BN, Maltzman J, O'Rourke L, Johnston S. An exploration of the association of Quality-of-Life (QOL) scores with tumor progression status in first line hormone receptor positive, HER2+ Metastatic Breast Cancer (MBC) patients treated with lapatinib plus letrozole or letrozole alone. Poster presented at the Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 2009. San Antonio, TX. [abstract] Cancer Res. 2009 Dec; 69(24 (Suppl)):5106. doi: 10.1158/0008-5472.SABCS-09-5106.
Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, Marks JR, Lissowska J, Brinton L, Peplonska B, Cunningham JM, Vierkant RA, Rider DN, Chenevix-Trench G, Webb PM, Beesley J, Chen X, Phelan C, Sutphen R, Sellers TA, Pearce L, Wu AH, Den Berg DV, Conti D, Elund CK, Anderson R, Goodman MT, Lurie G, Carney ME, Thompson PJ, Gayther SA, Ramus SJ, Jacobs I, Kjaer SK, Hogdall E, Blaakaer J, Hogdall C, Easton DF, Song H, Pharoah HDP, Whittemore AS, McGuire V, Quaye L, Anton-Culver H, Ziogas A, Terry KL, Cramer DW, Hankinson SE, Tworoger SS, Calingaert B, Chanock S, Sherman M, Garcia-Closas M. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2009 Mar;69(6):2349-57.